Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Entia Biosciences Inc. (ERGO) had Revenue of $0.05M for the most recently reported fiscal quarter, ending 2016-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2016-12-31

Income Statement Financials
Revenue	$0.05M
Net Income	$-0.43M
Cost of Goods Sold	$0.01M
Gross Profit	$0.04M
Operating Expenses	$0.43M
Operating Income	$-0.39M
Non-Operating Income/Expense	$-0.05M
Pre-Tax Income	$-0.43M
Normalized Pre-Tax Income	$-0.43M
Income after Taxes	$-0.43M
Income from Continuous Operations	$-0.43M
Consolidated Net Income/Loss	$-0.43M
Normalized Income after Taxes	$-0.43M
EBIT	$-0.39M
EBITDA	$-0.31M
Weighted-Average Shares Outstanding (Basic)	28.14M
Weighted-Average Shares Outstanding (Diluted)	28.14M
Earnings per Share (EPS) (Basic)	$-0.02
Earnings per Share (EPS) (Diluted)	$-0.02
Balance Sheet Financials
Current Assets	$0.23M
Property, Plant, and Equipment	$0.02M
Long-Term Assets	$0.20M
Total Assets	$0.44M
Current Liabilities	$2.11M
Long-Term Debt	$0.30M
Long-Term Liabilities	$0.30M
Total Liabilities	$2.41M
Common Equity	$-1.97M
Tangible Shareholders Equity	$-2.15M
Shareholders Equity	$-1.97M
Common Shares Outstanding	28.15M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-0.72M
Cash Flow from Investing Activities	$-0.01M
Cash Flow from Financial Activities	$0.77M
Beginning Cash	$0.02M
End Cash	$0.08M
Increase/Decrease in Cash	$0.05M
Stock-Based Compensation	$0.11M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.11
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-0.18
Debt to Equity Ratio	-0.53
Gross Margin	77.99%
Operating Margin	-838.61%
EBIT Margin	-838.61%
EBITDA Margin	--
Pre-Tax Profit Margin	-941.12%
Profit Margin	-941.12%
Free Cash Flow	$-0.72M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.10
Inventory Turnover	0.15
Receiveable Turnover	5.77
Days Sales in Receivables	15.60
Return on Equity	22.00%
Return on Tangible Equity	20.10%
Return on Assets	-98.55%
Return on Investments	25.97%
Book Value Per Share	$-0.07
Free Cash Flow per Share	$-0.03
Operating Cash Flow per Share	$-0.03

Data from Zacks Investment Research, Inc.